Cannabis Law Report

APRIL 28, 2023

(“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has commenced a Phase II clinical trial for its proprietary […] (..)

Clinical Trials 52

Clinical Trials Pharmaceutical Patients Business 52

Cannabis Law Report

SEPTEMBER 2, 2021

In Europe, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as pharmaceutical products. In the US, sales of medical flower and vaporised products remain dominant amongst unapproved medicines, but there is also an increase in sales of pharmaceuticals, mainly Epidiolex®.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Cannabinoids 105

Cannabis Law Report

AUGUST 24, 2021

Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19. TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. About FSD Pharma. FSD Pharma Inc.

Clinical Trials 105

Clinical Trials Treatment Pharmaceutical Concentrates 105

Cannabis Law Report

OCTOBER 26, 2021

Incannex Healthcare Limited (ASX: IHL) has engaged pharmaceutical manufacturing company Procaps S.A The agreement between the two companies will see Procaps making IHL-42X for Incannex’s Phase 2, Phase 3, and open-label clinical trials. to develop and manufacture soft gel capsules of Incannex’s cannabis medicine IHL-42X.

Clinical Trials 52

Clinical Trials Sleep Medicine Pharmaceutical 52

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JULY 19, 2021

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Collectively, between the two organizations we offer a full-service package from protocol development to timely and successful clinical trial execution.”.

Clinical Trials 98

Clinical Trials Research and Development Hybrid Medicine 98

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. “We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Los Angeles, California. www.InvestorBrandNetwork.com. 310.299.1717 Office.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Medical Marijuana Program Connection

JANUARY 2, 2024

–(BUSINESS WIRE)—- $LBPH #DEEs–Longboard Pharmaceuticals, Inc. LA JOLLA, Calif.–(BUSINESS

Pharmaceutical 69

Pharmaceutical Clinical Trials Data Medicine 69

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. This means that the medical and scientific communities can now celebrate broader access to research for the production of pharmaceutical products that are safer than smokable or vaporizable cannabis. Drug Enforcement Agency (DEA).

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

MARCH 30, 2019

The trials, to be tightly controlled in a hospital environment, are exempted from Japan’s Cannabis Control Act, which bans cannabis compounds generally. Epidiolex, manufactured by UK-based GW Pharmaceutical, was approved by the U.S. Japanese officials approve Epidiolex for clinical trials.

Clinical Trials 45

Clinical Trials Research and Development Epilepsy Environment 45

Project CBD

OCTOBER 10, 2019

Two compounds that target the endocannabinoid system are currently in development to treat scleroderma – and they’re already in clinical trials. Pharmaceutical researchers have their sights set on developing a drug that bypasses CB1 while boosting CB2.

Cannabinoids 224

Cannabinoids Clinical Trials Research and Development Pharmaceutical 224

Cannabis Law Report

JUNE 7, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at the H.C. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Business 52

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. As part of our continued R&D efforts we also look forward to advancing our PTSD and essential tremor programs, the nabiximols clinical trial program to support a U.S.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Medical Marijuana Program Connection

APRIL 12, 2023

BALTIMORE, MD–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for. Read More

Therapy 52

Therapy Pharmaceutical Clinical Trials Business 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. About Marinus Pharmaceuticals.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 9, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

Otherside Farms

JANUARY 24, 2019

Roberta Cilio and Orrin Devinsky, of the University of California, San Francisco and New York University, respectively, will investigate the use of Epidiolex, a 98 percent purified cannabidiol drug manufactured by GW Pharmaceuticals, of the United Kingdom. Source: FDA Approves Marijuana-Based Epilepsy Drug For Use On Kids In Clinical Trials.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

Cannabis Law Report

DECEMBER 9, 2021

08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1 and Phase 2 clinical trials. as medical consultants to the Company’s DMT stroke clinical research program. Moreau CEO of Algernon Pharmaceuticals Inc. “We

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. Patent protects methods of administering MYMD-1 for treating disorders associated with chronic inflammation, with a focus on fibrosis and asthma.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

JULY 7, 2021

Company plans to initiate Phase II trial with a leading academic institution. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. These efforts continue to support MyMD’s efforts to move forward in Phase 2 clinical studies. About MyMD Pharmaceuticals, Inc. For more information, visit www.mymd.com.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

MARCH 7, 2023

Incannex Healthcare Limited, a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, announced that it has engaged Catalent (Catalent) to develop and manufacture a cGMP-grade psilocybin drug product for: (1) use in Incannex’s proprietary psilocybin-assisted psychotherapy (..)

Clinical Trials 52

Clinical Trials Therapy Pharmaceutical Medicine 52

Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. I am so very proud of all Anebulo has achieved over the past 18 months, including building out a highly effective team, securing new intellectual property protection, preparing and starting a proof-of-concept clinical trial, advancing regulatory discussions with the U.S.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

SEPTEMBER 22, 2021

Accelerated timelines to clinical trials and expansion of drug development pipeline. Under the terms of the agreement OCT will use reasonable efforts to develop and commercialise: (i) at least one CBD derivative; (ii) at least one CBG derivative; and (iii) at least one THC derivative, as pharmaceutical drug products.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

OCTOBER 5, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Cannabinoids Events 40

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. About Supera-CBD.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Due to seizure cluster fluctuation in PCDH19-clustering epilepsy, novel epilepsy clinical trial designs may be needed for future studies. About Marinus Pharmaceuticals.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Medical Marijuana Program Connection

MARCH 29, 2023

a research focused bio-pharmaceutical company today announced that the first subject. NEW YORK & GREENWOOD VILLAGE, Colo.–(BUSINESS –(BUSINESS WIRE)–ANANDA Scientific Inc., Read More

Clinical Trials 52

Clinical Trials Treatment Pharmaceutical Patients 52

Cannabis Law Report

OCTOBER 5, 2021

MyMD to launch two simultaneous Phase 2 trials during the current quarter to study MYMD-1’s function in extending healthy lifespan and treating COVID-19-associated depression. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. We believe that the new data we are revealing today is an extraordinary achievement in the field of pharmaceutical cannabinoids,” said Adam Kaplin, M.D.,

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. tumor necrosis factor receptor I (TNFRI) and IL-6.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

AUGUST 7, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. We are pioneering a new kind of pharmaceutical company that prioritizes public benefit and is committed to sustainability, accountability, and transparency.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105